Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a leader in autoimmune diagnostics, providing specialized testing solutions through its CLIA-certified laboratory and proprietary AVISE® platform. This page serves as the definitive source for verified news and announcements related to the company’s advancements in rheumatology diagnostics, financial developments, and strategic initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study outcomes, and operational achievements. Our curated collection includes earnings reports, partnership announcements, and insights into biomarker research that drives Exagen’s industry-leading tests for conditions like lupus and rheumatoid arthritis.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards and medical accuracy. Bookmark this page to efficiently track Exagen’s progress in improving diagnostic clarity for autoimmune diseases while staying informed about its role in advancing personalized medicine.
Exagen Inc. (Nasdaq: XGN) reported record financial results for Q2 2021, achieving total revenue of $12.8 million, a 43% year-over-year increase, and a 21% rise from Q1 2021. Revenue from the AVISE® CTD test reached $10.4 million, marking a 94% increase from the previous year. The company delivered 33,328 tests, reflecting an 80% growth year-over-year. Despite these gains, operating expenses rose to $18.5 million, leading to a net loss of $6.4 million. Exagen maintains its full-year revenue guidance of $47 million to $49 million.
Exagen Inc. (Nasdaq: XGN) has appointed Ms. Ana Hooker as an independent member of its Board of Directors, effective July 29, 2021. Hooker brings extensive experience in clinical laboratories, having held senior roles in organizations like Exact Sciences. The addition is expected to bolster Exagen's growth strategy in autoimmune testing solutions. Exagen aims to enhance patient care through innovative testing products under its AVISE® brand, focusing on complex autoimmune diseases.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen (Nasdaq: XGN) will participate in the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. CEO Ron Rocca and CFO Kamal Adawi will host a virtual fireside chat on August 12 at 12:00 PM EST. The session can be accessed through Exagen’s website.
Exagen aims to advance care for autoimmune disease patients with innovative testing solutions, including products under its AVISE® brand. For more details, visit their website.
Exagen Inc. (Nasdaq: XGN) will announce its financial results for Q2 2021 on August 9, 2021, post-market close. Key executives, including CEO Ron Rocca and CFO Kamal Adawi, will lead a conference call at 4:30 PM Eastern Time to review the results. Interested parties can join the call by phone or through a webcast available on Exagen’s investor relations website. A replay of the call will be accessible until August 16, 2021. Exagen focuses on autoimmune testing solutions, aiming to enhance patient care through its AVISE® brand products.
Exagen Inc. (Nasdaq: XGN) announced the publication of a clinical utility study in Lupus & Science Medicine demonstrating the effectiveness of the AVISE Lupus test. Conducted with 12 rheumatology practices, the study revealed that the AVISE test enhances physician confidence in diagnosing systemic lupus erythematosus (SLE) and informs treatment decisions. The results showed increased certainty in SLE diagnoses with higher AVISE scores. Exagen aims to support rheumatologists in managing autoimmune diseases through innovative testing solutions.
Exagen Inc. (Nasdaq: XGN) announced that stockholders have elected Mr. Frank Stokes as an independent member of its Board of Directors during the Annual Meeting on June 17, 2021. Mr. Stokes will also chair the Audit Committee. His experience as a CFO and investment banker, particularly in the life sciences sector, is expected to contribute significantly to Exagen's growth strategy. He aims to enhance Exagen's commitment to improving patient care through innovative autoimmune testing solutions.
Exagen Inc. (Nasdaq: XGN) announced its participation in the William Blair 41st Annual Growth Stock Conference from June 1-3, 2021. The company will host a virtual fireside chat on June 2 at 11:20 AM EDT, featuring President and CEO Ron Rocca and CFO Kamal Adawi. Interested individuals can access the live webcast through Exagen’s website. Exagen focuses on autoimmune testing solutions, aiming to improve care for chronic autoimmune disease patients with innovative AVISE® testing products.
Exagen Inc. (XGN) reported a record revenue of $10.6 million for Q1 2021, up from $9.6 million in Q1 2020, driven by a significant increase in testing volumes. The company delivered 29,029 AVISE® CTD tests and achieved a record of 1,763 ordering healthcare providers. Operating expenses rose to $16.2 million, resulting in a net loss of $6.2 million, compared to a net loss of $5.6 million in the prior year. Exagen maintains its 2021 revenue guidance of $47 million to $49 million.
Exagen Inc. (Nasdaq: XGN) has entered a research collaboration and exclusive license agreement with Allegheny Health Network (AHN) to develop novel patented biomarkers for autoimmune diseases such as systemic lupus erythematosus (SLE). Exagen will gain exclusive rights to four distinct families of inventions and access to AHN's clinical biobank. The collaboration aims to enhance the existing AVISE® testing portfolio using advanced technology known as Cell-Bound Complement Activation Products (CB-CAPs), which were previously developed in conjunction with AHN researchers.
Exagen Inc. (Nasdaq: XGN) has announced its new campaign, 'Know With AVISE,' coinciding with Lupus Awareness Month. This initiative aims to educate the public on the importance of timely diagnosis and monitoring for Systemic Lupus Erythematosus (SLE). In collaboration with the Lupus Foundation of America and LupusChick, Exagen will focus on various stages of the lupus patient journey throughout May. The campaign highlights diagnostic challenges and health disparities while encouraging disease management. Exagen is committed to enhancing care for autoimmune disease patients through innovative testing solutions.
FAQ
What is the current stock price of Exagen (XGN)?
What is the market cap of Exagen (XGN)?
